Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB04 biosimilar etanercept PK comparison study in healthy volunteers
NCT06392074Phase 1Completed
- Sponsor
- mAbxience
- Start
- Mar 2024
- Primary completion
- May 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of etanercept (3 arms), sponsored by mAbxience. Primary endpoints: Area Under the Serum Concentration Versus Time Curve from Time Zero to Infinity and Maximum Observed Serum Concentration. Started Mar 2024; status: completed.
02
Drugs
etanercept
Beyond the preview
Go deeper on NCT06392074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06392074.